TATakashi Ando

Takashi Ando

*This is an algorithmically generated author record based on publicly available information.

Takashi Ando has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Osamu Handa

    Department of Gastroenterology, Kawasaki Medical School, Okayama 701-0192, Japan

    2 shared publications
  • Toshikazu Yoshikawa

    Department of Cancer ImmunoCell Regulation Kyoto Prefectural University of Medicine Kyoto Japan

    2 shared publications
  • Yuji Naito

    Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

    2 shared publications
  • Akihiro Asakawa

    Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan

    1 shared publication
  • Akio Inui

    Pharmacological Department of Herbal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    1 shared publication
  • Akira Okajima

    Department of Gastroenterology Social Insurance Kyoto Hospital Koyamashimofusa‐cho 27 Kita‐ku Kyoto 603‐8151 Japan

    1 shared publication

Latest Publications

  • Open Access

    Kyoto Classification-Based Predictive Factors Associated with the Development of Gastric Cancer After Helicobacter pylori Eradication: A Prospective Multicenter Observational Study

    by Shun Takayama, Osamu Dohi, Ryusuke Horie, Takeshi Yasuda, Tomoko Ochiai, Naoto Iwai, Eiko Imamoto, Tomohisa Takagi, Osamu Handa, Hideyuki Konishi, et al.

    Background/Objectives: This study aimed to identify specific endoscopic findings associated with the development of GC following successful H. pylori eradication. Methods: This prospective multicenter observational study included patients who underwent annual surveillance endoscopy after successful H. pylori eradication therapy between September 2013 and June 2019. Endoscopic findings were evaluated one year after eradication therapy and analyzed using the Kyoto Classification of Gastritis to identify factors associated with GC development. Results: A total of 465 patients were included, including 49 patients with GC and 416 patients without GC. At the initial endoscopic assessment (median, 0.96 years post-eradication), emergence of map-like redness and invisible regular arrangement of collecting venule (RAC) as independent predictors of GC (map-like redness: hazard ratio [HR], 2.561; 95% confidence interval [CI], 1.362–4.572; p = 0.003; invisible RAC: HR, 3.131; 95% CI, 1.078–9.091; p = 0.036). Patients with map-like redness or invisible RAC showed a significantly higher incidence of GC than those without map-like redness or invisible RAC (p < 0.001 and p < 0.001, respectively). Notably, map-like redness and visible RAC appeared in 13% and 28.4% of cases within the first year after eradication, respectively. Conclusions: Map-like redness and invisible RAC were identified as independent predictors of GC following H. pylori eradication and may serve as early predictive indicators, appearing within one year of successful eradication. This finding underscores the importance of early surveillance endoscopy in identifying patients at elevated risk for GC.


  • Impact of Helicobacter pylori Eradication on Circulating Adiponectin in Humans

    by Takashi Ando, Takeshi Ishikawa, Tomohisa Takagi, Eiko Imamoto, Etsuko Kishimoto, Akira Okajima, Kazuhiko Uchiyama, Osamu Handa, Nobuaki Yagi, Satoshi Kokura, et al.

    Background The relationship between Helicobacter pylori infection and metabolic syndrome is not well understood. Adiponectin is an adipose‐derived protein considered to play a significant role in the development of metabolic syndrome. The aim of this study was to clarify the influence of H. pylori infection on circulating adiponectin in humans. Methods In a prospective study, 456 patients underwent endoscopy and H. pylori testing. All of the 338 H. pylori ‐positive patients received eradication therapy. Treatment was successful in 241 patients. Circulating adiponectin and other metabolic parameters were measured at baseline in all patients and 12 weeks after eradication therapy in those initially positive for H. pylori. Results Circulating adiponectin levels were not different between H. pylori ‐positive and H. pylori ‐negative patients. In the group with successful eradication, levels of total adiponectin and each multimer form were significantly increased after therapy. Conversely, the levels of total adiponectin and high‐molecular‐weight adiponectin, but not middle‐molecular‐weight and low‐molecular‐weight adiponectin, were increased in the group with unsuccessful eradication after the therapy. Conclusions Eradication therapy of H. pylori increased circulating adiponectin levels in Japanese individuals and could be beneficial for preventing metabolic syndrome conditions.


  • Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype

    by Takashi Ando, Takeshi Ishikawa, Satoshi Kokura, Yuji Naito, Norimasa Yoshida, Toshikazu Yoshikawa